Zeta-associated protein-70 (ZAP-70), mostly assessed by flowcytometry (FC), recently emerged as reliable prognostic factor in chronic lymphocytic leukaemia (CLL) at presentation. We evaluated ZAP-70 expression in 156 CLL patients by immunohistochemistry (IHC) on formalin-fixed bone marrow (BM) biopsies at diagnosis. At presentation, 117 patients (75%) were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). ZAP-70 was expressed in neoplastic lymphocytes of 69 patients (44%). Concordance between ZAP-70 by IHC and ZAP-70 by FC, immunoglobulin heavy chain variable genes (IGHV) mutational status and CD38 expression was found in 41/46 (89%), 41/49 (80%) and in 60/88 (68%) tested cases, respectively. ZAP-70 expression significantly correlated with advanced Binet stage (B-C), diffuse BM infiltration, increased lactate dehydrogenase (LDH) and b2-microglobulin serum levels and lymphocyte doubling time o12 months. ZAP-70 positivity was significantly related to poorer time to progression (median 16 months vs 158 of ZAP-70-negative cases) (Po0.0001) and overall survival (median 106 months vs not reached) (P ¼ 0.0002); this correlation was confirmed at multivariate analysis. ZAP-70 expression correlated with poorer outcome also when evaluated only in the 117 stage A patients. In conclusion, immunohistological detection of ZAP-70 on formalin-fixed BM biopsies at diagnosis appears a useful methodological approach to identify patients with poor prognosis in CLL.
Introduction
Although the clinical course of B chronic lymphocytic leukaemia (CLL) is mostly indolent, in some cases the disease behaves aggressively. The availability of new treatments, such as purine analogues and monoclonal antibodies, capable of obtaining a complete remission in a substantial portion of patients and of prolonging the time to progression (TTP), recently rose the need of better assessing the prognosis of CLL at presentation. In fact, particularly in initial clinical stages, traditional available prognostic models cannot precisely predict in individual cases at diagnosis whether the course of the disease will be stable or progressive.
In recent years, a number of biological prognostic factors have been developed. 1 Among them, analysis of the mutational status of the expressed immunoglobulin heavy chain variable genes (IGHV) allowed to separate two subgroups within CLL. 2 Patients with leukaemic cells that express unmutated genes have more likely atypical morphology, advanced stage and relatively aggressive clinical course. Conversely, patients with CLL cells expressing IGHV genes with somatic mutation have frequently indolent disease. 3, 4 Such striking biological and clinical differences, raising the question whether the two categories of CLL represent different diseases, contrast with the rather unique gene profile assessed by microarray techniques. 5 The differences of gene expression are limited to a restricted number of genes, including the gene encoding zeta-associated protein 70 (ZAP-70), a 70-kDa z-chain CD3-receptor-associated protein tyrosine kinase that is normally expressed in T cells and natural killer cells and has a critical role in the initiation of T-cell signalling. 6, 7 In CLL cells, ZAP-70, according to recent studies, could enhance the effectiveness of immunoglobulin M (IgM) signalling 8 and produce an advantageous migratory and survival response, 9 thus contributing to aggressive clinical behaviour. The evaluation of the prognostic value of ZAP-70 in CLL has been performed during the last 3 years using a variety of methodological approaches, including reverse transcriptasepolymerase chain reaction (RT-PCR) analysis, flow-cytometry (FC) and immunohistochemistry (IHC) . Retrospective studies demonstrated a strong correlation between ZAP-70 expression and clinical behaviour, with ZAP-70 overexpressing cases showing a shorter TTP or time to initial therapy [10] [11] [12] [13] [14] [15] and, but only in some studies, reduced survival, 12, 13 suggesting that ZAP-70 is an independent prognostic factor. Data concerning ZAP-70 protein expression detected by IHC method in CLL are promising, but a standardized protocol has not been established yet for bone marrow (BM) samples. 10, 12, 16, 17 The use of BM trephine biopsies could represent a potentially suitable material to evaluate ZAP-70, as this tissue is in most cases, infiltrated by neoplastic lymphocytes and BM biopsy is largely included in the diagnostic evaluation of CLL patients. 18 In this study, we analysed the expression of ZAP-70 protein by IHC on BM biopsies taken at presentation of 156 patients with CLL seen at our institution in order to evaluate the prognostic value of this parameter.
Patients and methods

Patients
One hundred and fifty six patients who had a diagnosis of CLL at our institution from January 1986 to March 2005 were selected on the basis of the availability of BM biopsy taken within 6 months from the diagnosis and before any treatment. Diagnosis of CLL was based on standard morphological and immunophenotypical criteria. 19 At presentation, the following parameters were analysed: age, sex, stage according to Binet classification, pattern of BM infiltration, serum levels of lactate dehydrogenase (LDH) and b-2microglobulin. Lymphocyte doubling time was calculated according to Montserrat et al. 20 Disease progression was defined as a change to a more advanced clinical stage or the need for the treatment. Therapy was started according to standard criteria. 19 Initial treatment was alkylating agents in 71 patients, fludarabine7cyclophosphamide in 20.
We retrospectively evaluated ZAP-70 expression on BM biopsies taken at diagnosis in all 156 patients. In 14 of 156 patients, ZAP-70 expression was analysed in two sequential BM samples. The median time between the biopsies was 23 months (range 
Histology and IHC
BM biopsies were fixed in 10% neutral buffered formalin for 24-36 h, decalcified in ethylenediaminetetraacetic acid (EDTA) disodium salt acid buffer (Osteodec, Bio-optica, Milan, Italy) for 3 h, and conventionally embedded in paraffin. All cases were classified as classical CLL both on morphological and IHC criteria (CD79a þ , CD20 þ dim, CD5 þ , CD23 þ ). The pattern of BM involvement was categorized into four types: interstitial, nodular, mixed (interstitial þ nodular) and diffuse, according to Rozman et al. 18 Interstitial, nodular and mixed subtypes were put together into the non-diffuse group. IHC was performed on deparaffinized sections pretreated for 30 min in 10 mM citrate buffer (pH 7) in steam. Mouse anti-human monoclonal antibody (mAb) to ZAP-70 (clone 2F3.2, dilution 1/200; Upstate, Lake Placid, NY, USA) was used with a polymeric labelling two-step method (Super sensitivet IHC detection system, Biogenex, San Ramon, CA, USA) in an automated staining system (GenoMx i6000, Biogenex). Sections incubated without the primary antibody served as negative control. CD79a was used on serial sections to asses the pattern of distribution and the amount of CLL cells whereas with CD3 was assessed T-cell component. After determining that T cells were ZAP-70 positive as expected, cases of CLL were scored for nuclear and/or cytoplasmic ZAP-70 staining on a three-tier scale: negative (score 0); weakly positive (score 1 þ ); positive (score 2 þ ). Score 2 þ staining correspond to nuclear and cytoplasmic staining of T cells (Figure 1 ). Two pathologists evaluated the cases independently. The concordance rate was 100% in assessing negative and positive cases. The reproducibility of score 1 þ and score 2 þ cases was lower (85% of concordance); the discrepancies were easily resolved by consensus.
Flow-cytometry
Fresh whole-blood cells were stained for 15 min at room temperature with anti-CD19 and anti-CD5 mAb conjugated with PE-Cy7 and APC, respectively (Becton Dickinson Bioscience, San Diego, CA, USA). For CD38 staining, cells were incubated with phycoerythrin (PE)-conjugated anti-CD38 (Becton Dickinson Bioscience). 21 Cases with o7% CD38-positive cells were considered negative. 21, 22 For ZAP-70 determination, cells were fixed and permeabilized with Fix & Perm (Caltag Laboratories, Burlingame, CA, USA), according to the manufacturer's recommendations, and incubated with anti-ZAP-70 (clone 1E7.2) Alexa Fluor 488-conjugated mAb (Caltag) for 20 min at room temperature.
In all cases, at least 10 000 events have been acquired on a FACScalibur equipped with 488 argon ion laser and 635 diode laser and analysed with the CellQuest software (BD Biosciences, San Diego, CA, USA). Lymphocytes were gated on the basis of their morphological features (FSC vs SSC). T lymphocytes and CLL cells were identified for CD5 þ /CD19À and CD5 þ / CD19 þ expression, respectively. The expression of ZAP-70 on CLL cells was measured by using T cells as positive internal control and isotype-matched antibody as negative one. The cutoff value was set at 20% of ZAP-70-positive CLL cells. 12 
Determination of IGHV gene mutational status
Leukaemic cells were obtained from peripheral blood samples after isolation by Ficoll gradient. Total RNA was extracted using the guanidinium thiocyanate method and reverse-transcribed into complementary DNA (cDNA) using 200 U Superscript, RNAse H À Reverse transcriptase and random hexamers (Invitrogen, San Giuliano Milanese, Italy). The IGHV-D-J gene sequences were determined by amplifying with polymerase chain reaction (PCR) cDNA, using the appropriate sense IGHV leader primer and the antisense IGHC primer. 21, 22 Purified PCR products were sequenced directly using an automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). Sequence data were analysed using the international Immunogenetics database (IMGT, http://imgt.cines.fr) in order to determine the respective homology of each gene with the closest germline counterpart. The sequences with a germline homology X98% were considered unmutated, and those o98% mutated.
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Statistical analysis
Association of ZAP-70 positivity with characteristics of patients at presentation was tested using Fisher's exact test. Overall survival (OS) was defined as the time from diagnosis to death or last follow-up. TTP was calculated from the date of diagnosis to the date of progression or last follow-up. OS and TTP curves were estimated according to the Kaplan-Meier method. The association with prognostic factors was tested using the log-rank test. Univariate and multivariate analyses were performed using the Cox regression model, in order to obtain unadjusted and adjusted hazard ratios (HRs) and their 95% confidence intervals (95% CIs). The analyses have been performed using Intercooled Stata 8.0 for Windows (Stata Corp., College Station, TX, USA).
Results
Patients' data
Characteristics at presentation of the 156 patients are summarized in Table 1 . Men were 101 (65%). Median age at diagnosis was 62.5 years (range, 33-80 years).
At presentation, 117 (75%) patients were with Binet stage A, 27 (17%) stage B and 12 (8%) stage C. Median follow-up was 61 months (range 6-242). During this period, 65 patients were never treated and 91 needed treatment after a median of 17 months from presentation (range 2-197).
Histology and IHC data
Diffuse pattern of BM infiltration of disease was present in 48 cases (31%). Homogeneous ZAP-70 expression appeared as cytoplasmic and/or nuclear in neoplastic lymphocytes, and was, ZAP-70 by IHC in CLL bone marrow R Zanotti et al in most cases, less intense than reactive T cells. Larger cells within proliferative growth centres showed higher intensity. ZAP-70 was considered positive (score 1 þ and 2 þ ) in 69 CLL cases (44%). None of the 14 patients, in whom sequential samples of BM biopsies were evaluated, had changes in ZAP-70 expression over time.
At baseline, age and sex of patients were not associated with ZAP-70 expression. ZAP-70-positive cases were more frequent among patients with advanced Binet stage (B-C) at diagnosis (P ¼ 0.001), with diffuse BM infiltration (P ¼ 0.001), lymphocyte-doubling time o12 months (Po0.001) and levels of serum LDH and b2-microglobulin higher than normal values (P ¼ 0.005 and 0.008, respectively) ( Table 1) .
Correlation of ZAP-70 expression by IHC and FC
Concordance between ZAP-70 expression by FC and IHC was found in 41/46 (89%) tested cases. In 4/5 discordant cases, the percentage of ZAP-70-positive cells by FC was near the cutoff (defined as 20% of cells) ranging from 11 to 24%. Only in one case the percentage of positive cells was 70% by FC but negative by IHC. Two of the five discordant patients were ZAP-70 positive by IHC, but negative by FC, and required treatment, whereas two of three remaining cases (ZAP-70 negative by IHC) were not treated.
Correlation between ZAP-70 expression by (IHC) and CD38 expression assessed by FC
In 88/156 patients, CD38 expression was tested at diagnosis by FC: concordance with ZAP-70 expression was 68 using 7% as cutoff. With different cut-off points (20 and 30%) the concordance rate was similar (69%).
Correlation between ZAP-70 expression by IHC and the mutational status of IGHV gene
The mutational status of the IGHV gene was examined in 49 cases: 27 were mutated and 22 were unmutated. Of the patients in whom the IGHV gene had 98% or greater homology with a known germline IGHV gene, 81% (18/22) were ZAP-70 positive; 78% (21/27) of the patients with mutated IGHV gene were ZAP-70 negative. Overall, concordance between mutational status and ZAP-70 expression by IHC was 80% (39/49 cases). IGHV mutational status was analysed in three of the five cases discordant for ZAP-70 expression by FC Survival data TTP. Median TTP was 48 months, ranging from 2 to 242 months. Ninety-one patients (58%) experienced a progression and/or needed therapy after a median time of 17 months (range 2-197). Of the 91 treated patients, 58 were ZAP-70 positive by IHC (64%) and 33 ZAP-70 negative (36%). Table 2 shows the distribution of different Binet stages among treated patients at the time of treatment, according to ZAP-70 expression. An excess of Binet stage A was observed for treated ZAP-70-negative patients as compared to ZAP-70 positive (P ¼ 0.045). Table 3 ). The TTP stratified by ZAP-70 expression is shown in Figure 2a (P-value of the log-rank test was o0.0001). Median TTP of ZAP-70-negative patients was 158 months (range 2-242) and that of ZAP-70 positives was 16 months (range: 2-197). Binet stage and ZAP-70 effects were confirmed in multivariate analysis (Table 3) . A significant interaction was found between ZAP-70 expression and Binet stage (likelihood ratio tests P-value ¼ 0.0197), as extensively described below.
TTP of the 28 patients discordant for the expression of ZAP-70 by IHC and of CD38 by FC (median 62 months, range 2-146 months) was intermediate between that of the 31 ZAP-70/CD38-negative patients (median not reached, range 2-176 months) and that of the 29 ZAP-70/CD38-positive patients (median 20 months, range 2-143 months) (P ¼ 0.004). We repeated the same evaluation stratifying the group of discordant cases into 15 ZAP-70-negative/CD38-positive patients and 13 ZAP-70-positive/CD38-negative cases. Among ZAP-70-positive and -negative patients, respectively, TTP did not differ significantly according to the expression of CD38 (Figure 3) . TTP of the 10 cases discordant for ZAP-70 expression by IHC and IGHV mutational status was significantly better (median 64 months, range 6-122) than that of the 18 unmutated/ZAP-70 positive (median 16 months, range 2-54) (P ¼ 0.001) but not significantly different as compared to that of the 21 mutated/ ZAP-70 negative (median not reached, range 2-176) (P ¼ NS) (Figure 4 ). Further stratification of discordant patients was not applicable owing to the limited number of cases.
Overall survival. There have been 27 deaths (17%), all CLL related. The projected OS of all patients at 10 years was 6576% (s.e.). Sex and age did not affect OS, whereas Binet stage B/C (HR ¼ 6.34; 95% CI: 2.49-16.10), BM diffuse infiltration (HR ¼ 3.03; 95% CI: 1.40-6.61) and ZAP-70 positivity (HR ¼ 4.96; 95% CI: 2.14-11.49) were associated with poorer survival (Table 3) . Survival was strikingly different when stratified by ZAP-70 positivity by IHC: median survival of the 69 ZAP-70-positive patients was 106 months, whereas final survival for ZAP-70-negative subjects was higher than 75% (log rank P ¼ 0.0002) (Figure 2b) . Associations, but that of BM infiltration, were confirmed by adjusted Cox model (Table 3) .
OS of the 28 cases discordant for ZAP-70 expression by IHC and CD38 by FC was not significantly different as compared to that of ZAP-70/CD38-positive and ZAP-70/CD38-negative patients, probably owing to the low number of events (median not reached in all three groups). The evaluation of OS of the patients discordant for ZAP-70 expression by IHC and mutational status of IGHV was not possible because no events were observed in this subgroup.
Prognostic value of ZAP-70 expression by Binet stage
The association of ZAP-70 positivity with poorer TTP and OS was confirmed when we repeated the analyses on the 117 patients with Binet stage A. The unadjusted and adjusted HRs for TTP in ZAP-70-positive stage A patients were 4.15 (95% CI: 2.37-7.29) and 3.39 (95% CI: 1.08-6.06), respectively (Table 3) . Median TTP was not reached (range: 2-242) in ZAP-70-negative subjects and was 42 months (range: 2-197) in ZAP-70 positives (Po0.0001) (Figure 5a ). The unadjusted HR for OS was 5.32 (95% CI: 1.98-14.32); the adjusted one was 4.52 (95% CI: 1.59-12.83) ( Table 3 ). Median OS of the ZAP-70-positive patients was 111 months and was not reached that of ZAP-70-negative patients (P ¼ 0.0005). These results are shown in Figure 5b .
On considering the 39 patients in Binet stage B/C, no association was found between ZAP-70 positivity and either TTP or OS, possibly owing to the low number of patients. Table 3 Effect of prognostic factors on time to progression and overall survival: hazard ratios (95% CI) 
Discussion
Our study confirms the strong prognostic value of ZAP-70 protein expression on leukaemic cells of CLL, here detected by IHC in BM biopsies, both in terms of OS and TTP. In particular, in our study this marker appeared able to predict the clinical outcome of patients with early-phase CLL at diagnosis.
ZAP-70 is the most recent among the biological prognostic factors evaluated during the last years in order to predict the clinical course of CLL at presentation, and to plan a risk adapted therapy for each case particularly in young patients. Initially considered as a surrogate of IGHV mutational status, ZAP-70 was recently suggested to be an independent prognostic factor in CLL. 15 Over the last 3 years, the correlation between ZAP-70 expression and IGHV mutational status and/or the prognostic value of ZAP-70 were analysed in a number of clinical studies, among which six large series, [11] [12] [13] [14] [15] 24 which mostly exploited the use of FC to detect ZAP-70.
Following these studies, FC has been proposed for routine risk assessment in CLL, 11 although technical problems related to the type of monoclonal antibody employed and to the threshold (10 or 20%) of positivity are still not completely solved. In addition, FC is not simple to standardize for intracellular antigens as ZAP-70 25 and, moreover, fresh or frozen viable cells are needed, thus complicating the centralization in reference laboratories and impeding retrospective studies. 15, 17 The degree of concordance between ZAP-70 expression and IGHV mutational status was variable in the different series, ranging between 75 and 490%, [12] [13] [14] likely owing to the different techniques used. In particular, in the largest series analysed 14 the concordance rate between ZAP-70 expression evaluated by FC and IGHV mutation results was 77%.
ZAP-70 expression on neoplastic cells of various B-cell lymphomas has been evaluated by IHC analysis in two major studies 16, 17 including a limited number of cases of CLL (37 and 52, respectively). Nevertheless, in these studies IHC analysis was not performed on BM biopsies, but on lymph nodes and other tissues or clot sections. Our results suggest that routinely formalin-fixed, paraffin-embedded and decalcified BM trephine biopsies can represent a reliable material for assessing ZAP-70 expression for prognostic stratification of CLL cases. Preanalytical manipulation of tissue samples, including fixation and decalcification, appears as a critical point as difficulties in assessing ZAP-70 immunostaining on BM trephine biopsies was recently reported using Bouin fixation, 17 and a better evaluation of ZAP-70 immunostaining was observed when using clot sections compared with the corresponding BM biopsy sections. 16 In the paper by Carreras et al. 17 a 92% concordance between immunophenotypical and IHC evaluation of ZAP-70 was reported. This rate is comparable with our findings (concordance in 89% of the 46 evaluated cases). Concordance of ZAP-70 expression evaluated by IHC with mutational status of IGHV gene was 80%, comparable with the concordance of ZAP-70 expression by FC and mutational status of IGHV gene in other large series. 13, 14 TTP of the cases discordant for ZAP-70 expression by IHC and IGHV mutational status was significantly better than that of unmutated/ZAP-70-positive patients (P ¼ 0.001), but not significantly lower than that of mutated/ ZAP-70 negative. Unfortunately, we were unable to corroborate the reported association 26 between ZAP-70 positive/IGHV mutated cases and VH3-21 gene usage as also previously questioned. 27 In our series, only one out of six cases positive for ZAP-70 and carrying mutated IGHV genes expressed VH3-21 gene.
The concordance rate between ZAP-70 by IHC and CD38 expression by FC (68%) found in our series was similar to that reported by Del Giudice (59%), using the same cutoff point of 7%. This finding did not change significantly using different cutoff points (20 and 30%). The prognosis evaluated as TTP of discordant cases was intermediate between that of ZAP-70/ CD38-negative and of ZAP-70/CD38-positive patients, as reported by other authors. 15, 24 Although the combination of ZAP-70 with CD38 may contribute to better define the prognosis of CLL patients, nevertheless the results obtained stratifying our discordant cases suggest a stronger prognostic impact of ZAP-70. The limited number of discordant cases between ZAP-70 expression by FC and IHC does not permit to definitively ascertain which test performs better, although IGHV mutational status seems to correlate better with IHC results
Our study represents at our knowledge the largest series of CLL patients tested for ZAP-70 expression by IHC methods on BM biopsies.
Although BM biopsy is not considered mandatory for the diagnosis of CLL, it is widely in use for the prognostic evaluation of CLL patients 18 and differential diagnosis with other lymphoproliferative diseases. In our experience, less than 3% of cases of CLL had absent or limited and not diagnostic lymphoid infiltration (data not shown), in contrast with up to 10% negative BM biopsies reported in CLL by Sah et al. 28 Moreover, the use of BM biopsies in our study allowed us to evaluate retrospectively a large series of CLL patients with adequate follow-up (median 58 months).
In our study, ZAP-70 expression appeared to correlate with various adverse clinical prognostic parameters. In fact, in ZAP-70-positive patients we found a significant prevalence of advanced Binet stage, diffuse BM infiltration, increased serum levels of LDH and b2-microglobulin and lymphocyte doubling time (LDT) inferior to 12 months.
In the above-mentioned studies, evaluating the prognostic value of ZAP-70 expression in CLL, the influence of this marker on the disease outcome was assessed mainly in terms of treatment-free interval (TFI) 10, 11, 14, 15, 24 or TTP. 12 Only in two of these studies, 12, 13 as in the present study, a significant correlation between ZAP-70 and OS was demonstrated.
TFI or TTP of ZAP-70-positive and -negative patients respectively, widely varied in the different studies, ranging from 1.5 to 6.4 years for ZAP-70-positive patients and from 3.75 to 410 years for ZAP-70 negatives, according to the proportion of initial stages included in the series. [10] [11] [12] [13] [14] [15] In our study, TTP in ZAP-70-positive patients is shorter (16 months), likely owing to the high percentage of advanced stage at diagnosis (43%) in this group, and is comparable to TFI reported by Del Giudice et al. In our study, the difference of OS according to ZAP-70 expression was highly significant (P ¼ 0.0002); moreover, median OS of ZAP-70-positive stage A patients (9.1 years) was comparable to that reported by Crespo et al. 12 (7.5 years) and by Orchard et al. 13 (9.2 years) in the entire series, which included only 11% of B-C Binet stage. In ZAP-70-negative stage A subjects, median OS was not reached in our study (419.7 years) and in Crespo series, 12 whereas Orchard reported a median OS of 24.4 years in all ZAP-70-negative patients. 13 In conclusion, using a different technical approach, we confirmed the strong prognostic value of ZAP-70 in CLL. The analysis of ZAP-70 protein expression by immunochemistry on BM biopsies gave similar results in predicting TTP and survival, as compared to FC analysis on peripheral blood, which has been proposed as standard technique, but which still presents interlaboratory standardization problems. Moreover, IHC detection of ZAP-70 on BM biopsies could represent an alternative cost-effective method to FC. The predictive value of ZAP-70 appears particularly relevant in initial stage A patient, in whom an initial wait-and-watch policy is usually adopted. Within this subgroup of patients, ZAP-70-positive cases could be proposed for a closer follow-up and/or prospective clinical trials.
